Ontology highlight
ABSTRACT:
SUBMITTER: Long SA
PROVIDER: S-EPMC3425404 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature
Long S Alice SA Rieck Mary M Sanda Srinath S Bollyky Jennifer B JB Samuels Peter L PL Goland Robin R Ahmann Andrew A Rabinovitch Alex A Aggarwal Sudeepta S Phippard Deborah D Turka Laurence A LA Ehlers Mario R MR Bianchine Peter J PJ Boyle Karen D KD Adah Steven A SA Bluestone Jeffrey A JA Buckner Jane H JH Greenbaum Carla J CJ
Diabetes 20120620 9
Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in type 1 diabetic (T1D) patients. Nine T1D subjects were treated with 2-4 mg/day rapamycin orally for 3 months and 4.5 × 10(6) IU IL-2 s.c. three times per week for 1 month. β-Cell function was monitored by measuring C-peptide. Immunologic changes were monitored using flow c ...[more]